USD10
Actions SMMT
À propos de Summit TherapeuticsSummit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
USD10
Actions SMMT
À propos de Summit TherapeuticsSummit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Statistiques
FENÊTRE DE TRADING
Fermé
OUVRE À
Données insuffisantes
Capitalisation boursière
12,23 Md $US
PRIX D'OUVERTURE
17,40 $US
BAS (1 an)
13,83 $US